Qu Biologics enrolls the first patient in new Phase 2 Crohn’s Disease clinical trial VANCOUVER, British Columbia, July 25, 2018 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel platform of immunotherapies...

Treatment with Qu Biologics’ Novel Immune Therapy for Ulcerative Colitis Results in High Clinical and Endoscopic Response Rates and Histological Improvement VANCOUVER, British Columbia, Aug. 02, 2017 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a unique platform of immunotherapies...

High Response and Remission Rates in Anti-TNFα Naïve Patients Treated with Qu Biologics’ Novel Immune Therapy for Crohn’s Disease VANCOUVER, British Columbia, April 19, 2017 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a unique platform of immunotherapies...